Search
Search Results
-
Expression of the immune checkpoint molecules CD226 and TIGIT in preeclampsia patients
BackgroundImbalanced immune responses are involved in develo** preeclampsia (PE). We wish to explore the expression and potential changes of immune...
-
Immune Checkpoint Blockade Response Biomarkers
Cancer immunotherapy based on immune checkpoint blockade (ICB) has demonstrated durable clinical benefit in patients with immunogenic tumors,...
-
Immune Checkpoint Inhibitors in Urological Cancers
Over-expression of the immune checkpoint inhibitors is an important approach for malignant cells to escape the host immune system; therefore, the use...
-
Phosphatidylserine externalization as immune checkpoint in cancer
Cancer is the second leading cause of mortality worldwide. Despite recent advances in cancer treatment including immunotherapy with immune checkpoint...
-
Immune Checkpoint Therapy: A New Opportunity for Cancer Treatment
Due to improved understanding of the tumor biology and immunology, cancer immunotherapy has rapidly developed as a promising strategy to treat...
-
Expression of immune checkpoint molecules on adult and neonatal T-cells
Term and especially preterm neonates are much more susceptible to serious bacterial infections than adults. But not only the susceptibility to...
-
Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart
Immune-checkpoint inhibitors (ICIs) have revolutionized oncology, with nearly 50% of all patients with cancer eligible for treatment with ICIs....
-
Deciphering the Role of Immune-Checkpoint Inhibitors in Lung Cancer Treatment
Lung cancer is the leading cause of cancer-related fatalities worldwide in both men and women. Targeted therapy and chemotherapy have enhanced lung...
-
Targeting RNA N6-methyladenosine to synergize with immune checkpoint therapy
Cancer immunotherapy, especially immune checkpoint therapy, has revolutionized therapeutic options by reactivating the host immune system. However,...
-
Endocrine Consequences Following Immune Checkpoint Inhibitors Therapy
Immune checkpoint inhibitors (ICIs) are a novel drug category enhancing the patient’s immune response against tumors. Their approval in cancer...
-
PARP inhibitor and immune checkpoint inhibitor have synergism efficacy in gallbladder cancer
Gallbladder cancer (GBC) is an aggressive cancer with poor prognosis. PARP inhibitors (PARPi) target PARP enzymes and have shown efficacy in patients...
-
-
Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies
Longitudinal sampling of tumor tissue from patients with solid cancers, aside from melanoma and a few other cases, is often unfeasible, and thus may...
-
HLA-G: A Novel Immune Checkpoint for Solid Cancer Immunotherapy
Background: The distribution of human leukocyte antigen-G (HLA-G) is limited in physiological situations. Functionally, HLA-G is an important...
-
Combination of Photodynamic Therapy and Immune Checkpoint Blockade
Photodynamic therapy (PDT) for cancer not only strongly reduces tumor mass but can also induce or enhance immune responses against the tumor by...
-
GRIN2A mutation is a novel indicator of stratifying beneficiaries of immune checkpoint inhibitors in multiple cancers
Glutamate-NMDAR receptors (GRINs) have been reported to influence cancer immunogenicity; however, the relationship between GRIN alterations and the...
-
Tumor stroma-derived ANGPTL2 potentiates immune checkpoint inhibitor efficacy
Use of immune checkpoint inhibitors (ICIs) as cancer immunotherapy has advanced rapidly in the clinic. We recently reported that tumor stroma-derived...
-
Antigen presenting cells in cancer immunity and mediation of immune checkpoint blockade
Antigen-presenting cells (APCs) are pivotal mediators of immune responses. Their role has increasingly been spotlighted in the realm of cancer...
-
Inhibition of autophagy-related protein 7 enhances anti-tumor immune response and improves efficacy of immune checkpoint blockade in microsatellite instability colorectal cancer
BackgroundThe efficacy of anti-PD-1 therapy is primarily hindered by the limited T-cell immune response rate and immune evasion capacity of tumor...
-
Immune Checkpoint Blockade Therapy for Breast Cancer: Lessons from Epithelial–Mesenchymal Transition
Immune checkpoint blockade therapies have generated efficacious responses in certain tumor types; however, the responses of breast carcinomas have...
